Establishes guidelines for anti-amyloid treatment in Alzheimer’s disease, suggesting clear pathways for practice.
To establish recommendations for implementation of anti-amyloid monoclonal antibodies (mAbs) for treatment of Alzheimer’s disease (AD) by private practice neurologists.
No takes yet. Share an insight, caveat, or question.
Gelblum et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: